Medically reviewed by Jamin Brahmbhatt, MD Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced ...

The cancer cells may metastasize (spread) from the prostate to other parts of the body, particularly the bones and lymph nodes. Prostate cancer may cause pain, difficulty in urinating, problems ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients with castration-resistant PC have prolonged their survival.

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Dr Mohammad Mahmoud shares anticipated updates on evolving local treatments, PSMA-based therapies, and impactful genetic studies.

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

The Georgetown University Lombardi Comprehensive Cancer Center held a lecture on how certain white blood cells in the immune ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.